Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy
What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213 million? And is Adam an optimist?
We talk about all that and more on this week’s episode of “The Readout LOUD.” STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson’s exit from his decades-long tenure at the University of Pennsylvania. We also discuss the latest news in the life sciences, including the surprising collapse of a gene editing company, Eli Lilly’s pitch to consumers, and more.
